Pfizer Inc. (NYSE:PFE) Shares Sold by Rathbones Group PLC

Rathbones Group PLC lessened its position in Pfizer Inc. (NYSE:PFE - Free Report) by 3.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 585,057 shares of the biopharmaceutical company's stock after selling 20,034 shares during the period. Rathbones Group PLC's holdings in Pfizer were worth $15,522,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of PFE. Vanguard Group Inc. raised its holdings in Pfizer by 0.4% in the 4th quarter. Vanguard Group Inc. now owns 518,535,151 shares of the biopharmaceutical company's stock valued at $13,756,738,000 after acquiring an additional 2,285,276 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in shares of Pfizer by 19.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company's stock valued at $4,124,330,000 after purchasing an additional 25,315,159 shares during the period. Geode Capital Management LLC lifted its position in Pfizer by 2.5% during the fourth quarter. Geode Capital Management LLC now owns 120,589,782 shares of the biopharmaceutical company's stock worth $3,190,131,000 after buying an additional 2,923,537 shares during the period. Norges Bank purchased a new position in Pfizer during the fourth quarter worth about $2,328,986,000. Finally, Massachusetts Financial Services Co. MA grew its holdings in Pfizer by 7.5% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company's stock valued at $2,029,604,000 after buying an additional 5,350,381 shares during the period. Hedge funds and other institutional investors own 68.36% of the company's stock.

Insider Activity at Pfizer

In other Pfizer news, Director Ronald E. Blaylock acquired 19,457 shares of the company's stock in a transaction on Thursday, February 13th. The shares were bought at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the acquisition, the director now directly owns 27,707 shares of the company's stock, valued at $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.06% of the stock is currently owned by company insiders.

Pfizer Stock Up 1.0 %

Shares of PFE traded up $0.22 during mid-day trading on Friday, reaching $21.81. 27,621,434 shares of the stock traded hands, compared to its average volume of 40,111,002. The stock has a fifty day simple moving average of $25.33 and a 200 day simple moving average of $26.45. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The firm has a market cap of $123.68 billion, a price-to-earnings ratio of 15.35, a P/E/G ratio of 0.64 and a beta of 0.67.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.15. The firm had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm's quarterly revenue was up 24.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.10 EPS. Sell-side analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. UBS Group cut their price objective on shares of Pfizer from $28.00 to $24.00 and set a "neutral" rating on the stock in a report on Tuesday. The Goldman Sachs Group reissued a "neutral" rating and set a $25.00 price objective (down from $32.00) on shares of Pfizer in a research note on Tuesday. Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. Finally, Truist Financial cut their price objective on Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a report on Wednesday, December 18th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $31.07.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.